Blog

Many in the Alzheimer’s Disease (AD) community were disappointed when the Centers for Medicare & Medicaid Services (CMS) announced in late February it is not reconsidering national coverage determination (NCD) for Food and Drug Administration (FDA)-approved monoclonal antibodies directed against amyloid for the treatment of AD. Despite pressures from the AD community including patients, caregivers, families and …

 Brain Awareness Week 2023 Brain Awareness Week, a global campaign designed to advance enthusiasm and support for brain science, has been celebrated for nearly 30 years. The annual celebration is hosted by the Dana Foundation and is observed March 13 – 19, 2023.  Caring for your brain can prevent cognitive decline and neurodegenerative diseases such …

Less than two years after the FDA approved the first treatment for Alzheimer’s that was aimed at targeting the underlying disease process, it has approved a second similar agent. Payers are likely to cover the drug, one industry expert says, but they almost certainly will try to place restrictions on their coverage.  On Jan. 6, the …

Patients and families nationwide are excited by news of the FDA approval of Leqembi™ (lecanemab) as a new drug for Alzheimer’s Disease (AD). This disease modifying therapy (DMT) is a great first step forward for confronting this debilitating condition that impacts millions of Americans.   The drug is designed to target beta-amyloid, a protein in the brain that is thought …

FDA approval of LEQEMBI™ (lecanemab) as a new drug for Alzheimer’s Disease (AD) is a great first step forward for making disease modifying therapies (DMT) available to patients and families in their fight against this debilitating condition that impacts millions of Americans.   Importantly, this positive news marks a turning point for clinicians, payers and all stakeholders in …

November marks both National Caregivers and Alzheimer’s Awareness months, recognizing those with Alzheimer’s disease (AD) and their families and caregivers who play a significant role caring for people with this progressive brain disease.  SYNAPS Dx (SDx) honors those experiencing AD and the people who care for them not only during November, but also throughout the entire year.  In the …

SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), is pleased to announce the publication of “Morphometric imaging biomarker identifies Alzheimer’s disease even among mixed dementia patients” in Scientific Reports. “Up until now, there have been no autopsy-validated tests shown to accurately …

SYNAPS Dx is taking this opportunity to raise awareness about the significant progress in accurately diagnosing Alzheimer’s disease (AD). Introducing An Alternative Approach SYNAPS Dx recently presented some exciting new data for the DISCERN™  test at the 2022 Alzheimer’s Association International Conference (AAIC). DISCERN is a diagnostic skin test that assesses the factors directly related to the formation of synaptic connections …

SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), is pleased to announce the opening of a new, high-tech lab at the North Bethesda, MD Greencourt Innovation Center (GIC) for the national launch of DISCERN™, a minimally invasive diagnostic test to identify …

A significant barrier in Alzheimer’s Disease (AD) research for decades has been the inability to identify AD in people recently diagnosed with dementia and to distinguish AD from other forms of dementia. But as presented at the 2022 Alzheimer’s Association International Conference (AAIC) July 31-August 4, data have been presented to address that barrier. SYNAPS …